Abstract

Immunoconjugates (BR96-DOX) were prepared between chimeric monoclonal antibody BR96 and the anticancer drug doxorubicin. The monoclonal antibody binds an antigen related to Lewis Y that is abundantly expressed at the surface of cells from many human carcinomas; it has a high degree of tumor selectivity and is internalized after binding. BR96-DOX induced complete regressions and cures of xenografted human lung, breast, and colon carcinomas growing subcutaneously in athymic mice and cured 70 percent of mice bearing extensive metastases of a human lung carcinoma. Also, BR96-DOX cured 94 percent of athymic rats with subcutaneous human lung carcinoma, even though the rats, like humans and in contrast to mice, expressed the BR96 target antigen in normal tissues.

Keywords

Monoclonal antibodyImmunoconjugateDoxorubicinAntigenLewis lung carcinomaCancer researchChemistryCarcinomaMonoclonalAntibodyMedicineImmunologyChemotherapyCancerPathologyMetastasisInternal medicine

Affiliated Institutions

Related Publications

Publication Info

Year
1993
Type
article
Volume
261
Issue
5118
Pages
212-215
Citations
547
Access
Closed

External Links

View on DOI.org

Social Impact

Altmetric
PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

547
OpenAlex

Cite This

Pamela A. Trail, David Willner, Shirley J. Lasch et al. (1993). Cure of Xenografted Human Carcinomas by BR96-Doxorubicin Immunoconjugates. Science , 261 (5118) , 212-215. https://doi.org/10.1126/science.8327892

Identifiers

DOI
10.1126/science.8327892